Efficacy and acceptability of the S1P receptor in the treatment of multiple sclerosis: a meta-analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and acceptability of the S1P receptor in the treatment of multiple sclerosis: a meta-analysis
Authors
Keywords
-
Journal
NEUROLOGICAL SCIENCES
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-02-01
DOI
10.1007/s10072-021-05049-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
- (2019) Giancarlo Comi et al. LANCET NEUROLOGY
- Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
- (2018) Ludwig Kappos et al. LANCET
- Ozanimod for the treatment of relapsing remitting multiple sclerosis
- (2018) Ludwig Rasche et al. EXPERT OPINION ON PHARMACOTHERAPY
- Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis
- (2017) Burhan Z. Chaudhry et al. Neurotherapeutics
- Progressive multiple sclerosis: from pathogenic mechanisms to treatment
- (2016) Jorge Correale et al. BRAIN
- Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk
- (2016) Kunio Sugahara et al. BRITISH JOURNAL OF PHARMACOLOGY
- Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation
- (2016) Hsing-Chuan Tsai et al. DRUGS
- Fingolimod: therapeutic mechanisms and ocular adverse effects
- (2016) P Mandal et al. EYE
- Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial
- (2016) Ludwig Kappos et al. LANCET NEUROLOGY
- An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis
- (2015) Neeta Garg et al. Brain and Behavior
- A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
- (2014) T. L. Vollmer et al. JOURNAL OF NEUROLOGY
- Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial
- (2014) T. Olsson et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
- (2013) Krzysztof Selmaj et al. LANCET NEUROLOGY
- A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis
- (2012) T Saida et al. Multiple Sclerosis Journal
- Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
- (2012) Giancarlo Comi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies
- (2012) J. P. T. Higgins et al. Research Synthesis Methods
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Checking consistency in mixed treatment comparison meta-analysis
- (2010) S. Dias et al. STATISTICS IN MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search